WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H525744
CAS#: 114-80-7 (bromide)
Description: Neostigmine is a cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
Hodoodo Cat#: H525744
Name: Neostigmine bromide
CAS#: 114-80-7 (bromide)
Chemical Formula: C12H19BrN2O2
Exact Mass: 0.00
Molecular Weight: 303.200
Elemental Analysis: C, 47.54; H, 6.32; Br, 26.35; N, 9.24; O, 10.55
Related CAS #: 59-99-4 (cation) 114-80-7 (bromide) 51-60-5 (methylsulfate) 1212-37-9 (iodide) 588-17-0 (hydroxide)
Synonym: Neostigmine bromide
IUPAC/Chemical Name: 3-((dimethylcarbamoyl)oxy)-N,N,N-trimethylbenzenaminium bromide
InChi Key: LULNWZDBKTWDGK-UHFFFAOYSA-M
InChi Code: InChI=1S/C12H19N2O2.BrH/c1-13(2)12(15)16-11-8-6-7-10(9-11)14(3,4)5;/h6-9H,1-5H3;1H/q+1;/p-1
SMILES Code: C[N+](C)(C)C1=CC=CC(OC(N(C)C)=O)=C1.[Br-]
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 303.20 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Storms ML Bs, Stewart JT Phd, Warren FW Ms Rph. Stability of neostigmine methylsulfate injection at ambient temperature and 4 deg C in polypropylene syringes. Int J Pharm Compd. 2002 Nov-Dec;6(6):475-7. PubMed PMID: 23979474.
2: Shafer SL, Eisenach JC, Hood DD, Tong C. Cerebrospinal fluid pharmacokinetics and pharmacodynamics of intrathecal neostigmine methylsulfate in humans. Anesthesiology. 1998 Nov;89(5):1074-88. PubMed PMID: 9821995.
3: Hood DD, Eisenach JC, Tong C, Tommasi E, Yaksh TL. Cardiorespiratory and spinal cord blood flow effects of intrathecal neostigmine methylsulfate, clonidine, and their combination in sheep. Anesthesiology. 1995 Feb;82(2):428-35. PubMed PMID: 7856901.
4: Yaksh TL, Grafe MR, Malkmus S, Rathbun ML, Eisenach JC. Studies on the safety of chronically administered intrathecal neostigmine methylsulfate in rats and dogs. Anesthesiology. 1995 Feb;82(2):412-27. PubMed PMID: 7856900.
5: Hood DD, Eisenach JC, Tuttle R. Phase I safety assessment of intrathecal neostigmine methylsulfate in humans. Anesthesiology. 1995 Feb;82(2):331-43. PubMed PMID: 7856891.
6: Adams SB, MacHarg MA. Neostigmine methylsulfate delays gastric emptying of particulate markers in horses. Am J Vet Res. 1985 Dec;46(12):2498-9. PubMed PMID: 4083582.
7: Kucherenko ME, Havrylej VI. [Effect of x-irradiation, nicotinic acid and neostigmine methylsulfate on the interrelation between methylation and biosynthesis of tRNA]. Ukr Biokhim Zh. 1977 Sep-Oct;49(5):3-8. Ukrainian. PubMed PMID: 919054.
8: Kawabuchi M, Osame M, Watanabe S, Igata A, Kanaseki T. Myopathic changes at the end-plate region induced by neostigmine methylsulfate. Experientia. 1976 May 15;32(5):632-5. PubMed PMID: 179842.
9: Ward MD, Forbes MS, Johns TR. Neostigmine methylsulfate. Does it have a chronic effect as well as a transient one? Arch Neurol. 1975 Dec;32(12):808-13. PubMed PMID: 173268.
10: Kawabuchi M, Osame M, Watanabe S, Igata A, Kanaseki T. [Changes in the neuromuscular junction and striated muscle fiber following the administration of neostigmine methylsulfate in rats. A morphological observation (author's transl)]. Fukuoka Igaku Zasshi. 1975 Aug 25;66(8):500-11. Japanese. PubMed PMID: 1237456.
11: Kling RE. Structure of alkaline hydrolysis products of neostigmine methylsulfate and neostigmine bromide. J Assoc Off Anal Chem. 1974 May;57(3):721-4. PubMed PMID: 4833414.
12: Kling RE. UV spectrophotometric assay of neostigmine methylsulfate as the alkaline hydrolysis product, 3-dimethylaminophenol. J Assoc Off Anal Chem. 1971 Jan;54(1):21-6. PubMed PMID: 5162508.
13: Bridenbaugh PO, Churchll-Davidson HC. Response to tubocurarine chloride and its reversal by neostigmine methylsulfate in man. JAMA. 1968 Feb 19;203(8):541-4. PubMed PMID: 5694188.
14: LONG JP, ECKSTEIN JW. Ganglionic actions of neostigmine methylsulfate. J Pharmacol Exp Ther. 1961 Aug;133:216-22. PubMed PMID: 13763330.
15: GARVERICK WW, BURCH GR. Treatment of equine colic with neostigmine methylsulfate. J Am Vet Med Assoc. 1954 Jun;124(927):472-3. PubMed PMID: 13162911.
16: TEITELBAUM HA, VYNER HL. Neostigmine methylsulfate therapy in hemiplegia. Arch Neurol Psychiatry. 1949 Jul;62(1):93-8. PubMed PMID: 18147411.
17: HINMAN CH, ROBY CC. Tolerance trial of neostigmine methylsulfate in pregnancy. Am J Obstet Gynecol. 1949 Mar;57(3):586-8. PubMed PMID: 18123869.
18: BLATTNER RJ, GOODFRIEND J, WEBB BD. The use of neostigmine methylsulfate in infectious neuronitis; report of a case with involvement of respiratory muscles. J Am Med Assoc. 1947 Aug 9;134(15):1235-7. PubMed PMID: 20253936.
19: BELL JE Jr, BOONE JA. Neostigmine methylsulfate an apparent specific for arachnidism (black widow spider bite). J Am Med Assoc. 1945 Dec 8;129:1016. PubMed PMID: 21003747.
